As part of our ongoing aim to bring you reports of new developments, we have added a review on VESTIGE, an international, phase 4, randomised, double-blind, placebo-controlled trial which combined traditional lung function assessments, patient-reported outcomes, biomarkers and novel imaging outcomes to investigate dupilumab’s mechanism of action in patients with uncontrolled, moderate-to-severe type 2 asthma.
Independent commentary for the review has been provided by Professor Greg King, Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research, staff specialist in the Department of Respiratory and Sleep Medicine at Royal North Shore Hospital, Medical Director of the Respiratory Investigation Unit and Conjoint Professor of the Northern Clinical School of the University of Sydney.
Please login below to download this issue (PDF)